Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio’s pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction. SAN FRANCISCO, June 01, 2022 (GLOBE NEWSWIRE) — Recardio’s Phase 2 trial results demonstrated the excellent […]